Corporate green goals driving PAT adoption

GlaxoSmithKline plant managers are jumping on the process analytical technology train. But process control is not the sole driver. GSK, like other drugmakers, is seeing PAT provide a boost for its sustainability efforts.

The trend is currently most apparent in its pilot plants, according to PharmaManufacturing.com. Managers trying to reduce cycle times and realize energy and cost savings are considering and adopting the technology.

In a recent survey conducted by the online magazine, ten percent of respondents say that sustainability has become a key driver of their PAT efforts. About half of the 50 respondents say they see PAT as a means toward sustainability and green practices.

PAT has "moved up in status, and moved upstream in the development cycle," according to the article. "Manufacturers are beginning to equate PAT with reducing the environmental impact of processes."

- here's the article

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.